January 2024 updates to the website

The website has now been updated following January's LSCMMG

The following guidelines have been added/updated:

High strength fluoride toothpastes position statement - added

The following medicines have been added/ updated following the Clinical Effectiveness Group (CEG) meeting:

Ranolazine - as adjunctive therapy in the treatment of stable angina in patients inadequately controlled or intolerant of first-line antianginal therapies (RAG update)

Bimekizumab - active psoriatic arthritis (NICE TA916)

Bimekizumab - axial spondyloarthritis (NICE TA918)

Rimegepant - treating migraine (NICE TA919)

Tofacitinib - active ankylosing spondylitis (NICE TA920)

Mirikizumab - moderately to severely active ulcerative colitis (NICE TA925)

Baricitinib - severe alopecia areata (NICE TA926)

The following Items will be updated and added to the website following the next Clinical Effectivness Group (CEG) Meeting:

Empagliflozin - chronic kidney disease (NICE TA942)